AIxCrypto Holdings (AIXC) Registration filing summary

Company overview and business model

• Early clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer, with lead program QN-302 in Phase 1a clinical trials and a preclinical Pan-RAS program targeting oncogene protein interactions.

• Recent strategic investment in Marizyme, Inc. for commercialization of DuraGraft, with potential royalty payments tied to U.S. sales milestones.

• Divested former diagnostics business in 2023, now focused solely on oncology therapeutics and related investments.

Financial performance and metrics

• As of March 31, 2024, reported a working capital deficiency and recurring operating losses, raising substantial doubt about ability to continue as a going concern without additional funding.

• Net tangible book value as of March 31, 2024 was approximately $(3.5) million, or $(0.54) per share.

• Recent asset sale resulted in a loss from discontinued operations in Q2 2024.

Use of proceeds and capital allocation

• Estimated net proceeds of up to $3.6 million will be used for operations, advancement of clinical and preclinical programs, accelerated repayment of outstanding debentures, required payments on a senior note, potential expansion of the Marizyme relationship, general working capital, and possible future acquisitions.

• Management retains broad discretion over allocation of proceeds.